In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, ...

【导读】脑内出血（ICH）是严重类型的脑卒中，具有高死亡率和有限的选择治疗。12月23日，郑大一附院与中国科学院以及台北医学大学研究人员合作共同在期刊《Cell Death&Disease》上发表了研究论文，题为“Sphk1/S1P pathway ...

Jupiter Neurosciences (JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims ...

While several biologic agents that block IL-1β are currently approved for therapeutic use, blocking IL-1β alone only addresses one of the pathways important for NLRP3-driven diseases.

NLRP3 inflammasome activation, pro-inflammatory cytokine production and pyroptosis are key features of inflammation that contribute to liver fibrosis progression, cirrhosis and end-stage liver failure ...

Nanjing Mingde New Drug Research Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation.